Pancreatic Cancer Research

ResearcherShanghai UniversityActive in the last 2 years

Shipeng He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6673-5956; OpenAlex author ID A5008417020. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 3

  1. Discovery of Potent PDEδ/NAMPT Dual Inhibitors: Preclinical Evaluation in KRAS Mutant Pancreatic Cancer Cells. Last author DOI 10.1021/acs.jmedchem.4c02636↗
  2. Targeted delivery of a PROTAC induced PDEδ degrader by a biomimetic drug delivery system for enhanced cytotoxicity against pancreatic cancer cells. First author PMID 35411249↗
  3. Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer. Co-author DOI 10.1002/anie.201915896↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chunquan Sheng · 2 shared papers, 2020–2025 · strength 0.39
  2. Yaojin Zhu · 1 shared paper, 2025 · strength 0.26
  3. Hui Cai · 1 shared paper, 2022 · strength 0.14
  4. Ruyu Fan · 1 shared paper, 2022 · strength 0.14
  5. Huafei Li · 1 shared paper, 2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.